Experimental Therapeutics Programme

Biology Section

Head of Section:  Carmen Blanco
Publications in the last five years
Pages 1 - 2 - 3
  • Martínez González S, Hernández AI, Varela C, Rodríguez-Arístegui S, Alvarez RM, García AB, Lorenzo M, Rivero V, Oyarzabal J, Rabal O, Bischoff JR, Albarrán M, Cebriá A, Alfonso P, Link W, Fominaya J, Pastor J (2012). Imidazo[1,2-a]pyrazines as novel PI3K inhibitors. Bioorg Med Chem Lett 22, 1874-1878.
  • Martínez González S, Hernández AI, Varela C, Rodríguez-Arístegui S, Lorenzo M, Rodríguez A, Rivero V, Martín JI, Saluste CG, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán M, Alfonso P, García-Serelde B, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link,W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Pastor J (2012). Identification of ETP-46321, apotent and orallybioavailable PI3K a, d inhibitor Bioorg Med Chem Lett 22, 3460-3466.
  • Pastor J, Oyarzabal J, Saluste G, Alvarez RM, Rivero V, Ramos F, Cendón E, Blanco-Aparicio C, Ajenjo N, Cebriá A, Albarrán MI, Cebrián D, Corrionero A, Fominaya J, Montoya G, Mazzorana M (2012). Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors. Bioorg Med Chem Lett 22, 1591-1597.
Pages 1 - 2 - 3